104 related articles for article (PubMed ID: 17495449)
1. Development of IgA nephropathy-like disease with high serum IgA levels and increased proportion of polymeric IgA in Beta-1,4-galactosyltransferase-deficient mice.
Nishie T; Miyaishi O; Azuma H; Kameyama A; Naruse C; Hashimoto N; Yokoyama H; Narimatsu H; Wada T; Asano M
Contrib Nephrol; 2007; 157():125-8. PubMed ID: 17495449
[TBL] [Abstract][Full Text] [Related]
2. Development of immunoglobulin A nephropathy- like disease in beta-1,4-galactosyltransferase-I-deficient mice.
Nishie T; Miyaishi O; Azuma H; Kameyama A; Naruse C; Hashimoto N; Yokoyama H; Narimatsu H; Wada T; Asano M
Am J Pathol; 2007 Feb; 170(2):447-56. PubMed ID: 17255313
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of IgA nephropathy.
Feehally J; Allen AC
Ann Med Interne (Paris); 1999 Feb; 150(2):91-8. PubMed ID: 10392257
[TBL] [Abstract][Full Text] [Related]
4. Structural features of IgA molecules which contribute to IgA nephropathy.
Feehally J; Allen AC
J Nephrol; 1999; 12(2):59-65. PubMed ID: 10378660
[TBL] [Abstract][Full Text] [Related]
5. The Association of rs1047763 and rs1008898 of C1GALT1 with IgA Nephropathy Risk: A Global Meta-Analysis.
Nie R; Cheng G; Zhang J; Dong Y; Wang C; Liu J; Qin X
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):95-103. PubMed ID: 28636500
[TBL] [Abstract][Full Text] [Related]
6. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy.
Barratt J; Smith AC; Feehally J
Nephrology (Carlton); 2007 Jun; 12(3):275-84. PubMed ID: 17498123
[TBL] [Abstract][Full Text] [Related]
7. Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy.
Allen AC; Topham PS; Harper SJ; Feehally J
Nephrol Dial Transplant; 1997 Apr; 12(4):701-6. PubMed ID: 9140997
[TBL] [Abstract][Full Text] [Related]
8. Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy.
Oortwijn BD; Roos A; Royle L; van Gijlswijk-Janssen DJ; Faber-Krol MC; Eijgenraam JW; Dwek RA; Daha MR; Rudd PM; van Kooten C
J Am Soc Nephrol; 2006 Dec; 17(12):3529-39. PubMed ID: 17050773
[TBL] [Abstract][Full Text] [Related]
9. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system.
Novak J; Moldoveanu Z; Julian BA; Raska M; Wyatt RJ; Suzuki Y; Tomino Y; Gharavi AG; Mestecky J; Suzuki H
Adv Otorhinolaryngol; 2011; 72():60-3. PubMed ID: 21865691
[TBL] [Abstract][Full Text] [Related]
10. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy.
Xu LX; Zhao MH
Kidney Int; 2005 Jul; 68(1):167-72. PubMed ID: 15954905
[TBL] [Abstract][Full Text] [Related]
11. Different glycosylation profile of serum IgA1 in IgA nephropathy according to the glomerular basement membrane thickness: normal versus thin.
Linossier MT; Palle S; Berthoux F
Am J Kidney Dis; 2003 Mar; 41(3):558-64. PubMed ID: 12612978
[TBL] [Abstract][Full Text] [Related]
12. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.
Tissandié E; Morelle W; Berthelot L; Vrtovsnik F; Daugas E; Walker F; Lebrec D; Trawalé JM; Francoz C; Durand F; Moura IC; Paradis V; Moreau R; Monteiro RC
Kidney Int; 2011 Dec; 80(12):1352-63. PubMed ID: 21866091
[TBL] [Abstract][Full Text] [Related]
13. B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy.
Buck KS; Smith AC; Molyneux K; El-Barbary H; Feehally J; Barratt J
Kidney Int; 2008 May; 73(10):1128-36. PubMed ID: 18322546
[TBL] [Abstract][Full Text] [Related]
14. IgA nephropathy enigma.
Mestecky J; Novak J; Moldoveanu Z; Raska M
Clin Immunol; 2016 Nov; 172():72-77. PubMed ID: 27444044
[TBL] [Abstract][Full Text] [Related]
15. Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy.
Qin W; Zhou Q; Yang LC; Li Z; Su BH; Luo H; Fan JM
J Intern Med; 2005 Nov; 258(5):467-77. PubMed ID: 16238683
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy.
Hiki Y; Odani H; Takahashi M; Yasuda Y; Nishimoto A; Iwase H; Shinzato T; Kobayashi Y; Maeda K
Kidney Int; 2001 Mar; 59(3):1077-85. PubMed ID: 11231363
[TBL] [Abstract][Full Text] [Related]
17. The glycans deficiencies of macromolecular IgA1 is a contributory factor of variable pathological phenotypes of IgA nephropathy.
Xu LX; Yan Y; Zhang JJ; Zhang Y; Zhao MH
Clin Exp Immunol; 2005 Dec; 142(3):569-75. PubMed ID: 16297170
[TBL] [Abstract][Full Text] [Related]
18. O-glycosylation of serum IgD in IgA nephropathy.
Smith AC; de Wolff JF; Molyneux K; Feehally J; Barratt J
J Am Soc Nephrol; 2006 Apr; 17(4):1192-9. PubMed ID: 16510764
[TBL] [Abstract][Full Text] [Related]
19. Quantitative change of IgA hinge O-glycan composition is a novel marker of therapeutic responses of IgA nephropathy.
Iwatani H; Inoue T; Wada Y; Nagasawa Y; Yamamoto R; Iijima H; Takehara T; Imai E; Rakugi H; Isaka Y
Biochem Biophys Res Commun; 2012 Nov; 428(3):339-42. PubMed ID: 23098908
[TBL] [Abstract][Full Text] [Related]
20. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1.
Suzuki H; Moldoveanu Z; Hall S; Brown R; Julian BA; Wyatt RJ; Tomana M; Tomino Y; Novak J; Mestecky J
Contrib Nephrol; 2007; 157():129-33. PubMed ID: 17495450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
